Unity Biotechnology

Bcl-xL inhibition (senolytic) · Diabetic macular edema, wet AMD

Phase 2Senolytics

Mechanism

Bcl-xL inhibition (senolytic)

Intervention class

Small molecule senolytic

Indication

Diabetic macular edema, wet AMD

Stage

Phase 2

Evidence

human

Funding

NASDAQ: UBX

Backers

Public

Overview

The bellwether for senolytics in humans. UBX1325 clears senescent cells in the retina; Phase 2 data in DME has shown durable vision gains competitive with anti-VEGF. Proof that selectively killing senescent cells can move a clinical endpoint.

Technology

Unity Biotechnology works in Senolytics — Drugs that hunt down and kill the 'zombie' cells that drive aging.

Read the Senolytics brief →

Related companies

Calico

Multiple (cellular senescence, neurodeg.)

Insilico Medicine

TNIK inhibition (anti-fibrotic / senescence)

Dorian Therapeutics

USP7 inhibition (senolytic)

Cambrian BioPharma

Multiple (mitophagy, senescence, mTOR)

Company website / source ↗ Open the interactive map →

◢ Boom-cycle briefing

Get ahead of the next biotech boom.

New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.

Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.